- Home
- BFRI vs GTBP Comparison
BFRI vs GTBP Comparison
Compare BFRI & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRI
- GTBP
- Stock Information
- Founded
- BFRI 1997
- GTBP 1965
- Country
- BFRI United States
- GTBP United States
- Employees
- BFRI N/A
- GTBP N/A
- Industry
- BFRI Biotechnology: Pharmaceutical Preparations
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- BFRI Health Care
- GTBP Health Care
- Exchange
- BFRI Nasdaq
- GTBP Nasdaq
- Market Cap
- BFRI 6.2M
- GTBP 6.6M
- IPO Year
- BFRI 2021
- GTBP N/A
- Fundamental
- Price
- BFRI $0.98
- GTBP $3.28
- Analyst Decision
- BFRI Strong Buy
- GTBP Strong Buy
- Analyst Count
- BFRI 1
- GTBP 1
- Target Price
- BFRI $7.00
- GTBP $11.00
- AVG Volume (30 Days)
- BFRI 990.2K
- GTBP 1.0M
- Earning Date
- BFRI 11-13-2024
- GTBP 11-14-2024
- Dividend Yield
- BFRI N/A
- GTBP N/A
- EPS Growth
- BFRI N/A
- GTBP N/A
- EPS
- BFRI N/A
- GTBP N/A
- Revenue
- BFRI $35,358,000.00
- GTBP N/A
- Revenue This Year
- BFRI $17.69
- GTBP N/A
- Revenue Next Year
- BFRI $19.71
- GTBP N/A
- P/E Ratio
- BFRI N/A
- GTBP N/A
- Revenue Growth
- BFRI 5.17
- GTBP N/A
- 52 Week Low
- BFRI $0.61
- GTBP $1.72
- 52 Week High
- BFRI $3.90
- GTBP $10.66
- Technical
- Relative Strength Index (RSI)
- BFRI 52.63
- GTBP 53.29
- Support Level
- BFRI $0.94
- GTBP $1.72
- Resistance Level
- BFRI $1.06
- GTBP $4.10
- Average True Range (ATR)
- BFRI 0.12
- GTBP 0.47
- MACD
- BFRI -0.01
- GTBP -0.01
- Stochastic Oscillator
- BFRI 28.89
- GTBP 45.38
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.